Exact Sciences Introduces the Oncotype MAP™ Pan-Cancer Tissue Test to Help Guide Treatment for Patients with Advanced Cancer

Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients

Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020

New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results

New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates for Comparing Colorectal Cancer Screening Methods

EXACT SCIENCES HIGHLIGHTS THE OPPORTUNITY TO SEEK SCREENING WITH COLOGUARD® THROUGH TELEHEALTH

FIGHT COLORECTAL CANCER RECEIVES GRANT FROM EXACT SCIENCES TO LAUNCH PROGRAM AIMED AT REDUCING PATIENT BARRIERS TO COLORECTAL CANCER SCREENING

Dr. David Ahlquist, Co-Inventor of Cologuard, Named a Fellow of the National Academy of Inventors

Cologuard® Gains FDA Approval for Use in Younger Americans, Ages 45 to 49

Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work and Fortune

Exact Sciences And Genomic Health To Combine, Creating Leading Global Cancer Diagnostics Company

Exact Sciences Designated a Great Place to Work-Certified™ Company in 2019